Robert Rahimi
Hepatology · Dallas, TXNPI 1093927188
Payments from drug & device makers
Across 345 payments — averaging $1905.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$297K
- Bausch Health US, LLC$142K
- Gilead$94K
- AstraZeneca$52K
- Grifols Therapeutics LLC$36K
- Mirum Pharmaceuticals, Inc.$15K
- plus $23K from 21 others
Across 19 payments — averaging $2063.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$39K
What the payments were for
- Consulting fees$12,07566%
- Speaking & faculty fees$1,86010%
- Food & beverage$4,22423%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 38 | $296,794 |
| Bausch Health US, LLC | 86 | $141,896 |
| Gilead | 36 | $93,715 |
| AstraZeneca(2 entities) | 3 | $51,886 |
| Grifols Therapeutics LLC | 3 | $35,563 |
| Mirum Pharmaceuticals, Inc. | 4 | $14,935 |
| Mallinckrodt Hospital Products Inc. | 5 | $10,203 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $5,184 |
| Boehringer Ingelheim International GmbH | 46 | $4,962 |
| AbbVie | 60 | $1,391 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $145 |
| Shionogi Inc | 8 | $143 |
| Dynavax Technologies Corporation | 1 | $120 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $118 |
| Intercept Pharmaceuticals, Inc. | 5 | $110 |
| Ipsen Biopharmaceuticals, Inc | 4 | $95 |
| Dova Pharmaceuticals | 5 | $87 |
| Intra-sana Laboratories | 1 | $25 |
| Orphalan Inc | 1 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $22 |
| Ardelyx, Inc. | 1 | $20 |
| Eton Pharmaceuticals, Inc. | 1 | $19 |
| Merck | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIFAXAN$4,649
- TERLIVAZ$2,128
- Mavyret$239
- Heplisav-B$120
- LIVTENCITY$119
How this compares
$657,540 in reported general payments places this provider in the 75th percentile of 22 hepatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 12 | $41,518 |
| Sirolimus | 24 | $8,539 |
| Tacrolimus | 43 | $6,524 |
| Ursodiol | 50 | $4,732 |
| Mycophenolic AcidMycophenolate Sodium | 15 | $4,374 |
| Mycophenolate Mofetil | 24 | $1,315 |
| Entecavir | 20 | $1,302 |
| Lactulose | 19 | $639 |
| Spironolactone | 36 | $495 |
| Amiloride Hcl | 12 | $325 |
| Furosemide | 60 | $305 |
| Lansoprazole | 11 | $205 |
| Prednisone | 14 | $86 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $5,184 | $41,51812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 22 hepatology providers in Texas.
Other hepatology in Dallas
- Amit SingalDallas$1.6M
- Marlyn MayoDallas$954K
- William LeeDallas$925K
- Willis MaddreyDallas$289K
- Gary DavisDallas$9K
- Maria Lepe-SuasteguiDallas$4K
- Ussama GhummanDallas$1K
- Sarah LieberDallas$285
- Rashmee PatilMcAllen$3.3M
- Hesham ElgouhariDenison$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.